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ease at a genetic level. In the TMC Worldwide Gene
Therapy Enrollment Report,1 more than 2100 patients
received gene therapy in 1996 (more than 1700 of these
Objective: Nitric oxide regulates vascular tone, inhibits platelet aggrega-
tion, and inhibits leukocyte adhesion, all of which are important modu-
lators of ischemia-reperfusion injury. This study aimed to determine the
effects of endothelial constitutive nitric oxide synthase gene transfer on
ischemia-reperfusion injury in a rat lung transplant model. Methods: In
group I, donor animals were injected intravenously with 5 × 109 pfu of
adenovirus-encoding endothelial constitutive nitric oxide synthase.
Groups II and III served as controls, whereby donor animals were inject-
ed with either 5 × 109 pfu of adenovirus encoding β-galactosidase or
saline solution, respectively. Twenty-four hours after injection, left lungs
were harvested and preserved for 18 hours at 4°C, then implanted into
isogeneic recipients, which were put to death 24 hours later. Re-
combinant endothelial constitutive nitric oxide synthase gene expression
was evaluated by Western blotting and immunohistochemistry. Lung
grafts were assessed by measuring arterial oxygenation, myeloperoxidase
activity, and wet/dry weight ratios. Results: Western blotting confirmed
the overexpression of endothelial constitutive nitric oxide synthase in
lungs so transfected compared with controls. Twenty-four hours after
reperfusion, mean arterial oxygenation was significantly improved in
group I compared with group II and III controls (189.4 ± 47.1 mm Hg vs
71.7 ± 8.9 mm Hg and 67.8 ± 12.2 mm Hg, P = .02, P = .01, respective-
ly). Myeloperoxidase activity, a reflection of tissue neutrophil sequestra-
tion, was also significantly reduced in group I compared with groups II
and III (0.136 ± 0.038 ∆OD/mg/min vs 0.587 ± 0.077 and 0.489 ± 0.126
∆OD/mg/min, P = .001, P = .01, respectively). Conclusion: Adenovirus-
mediated gene transfer with endothelial constitutive nitric oxide synthase
ameliorates ischemia-reperfusion injury as manifested by significantly
improved oxygenation and decreased neutrophil sequestration in trans-
planted lung isografts. Endothelial constitutive nitric oxide synthase gene
transfer may reduce acute lung dysfunction after lung transplantation.
(J Thorac Cardiovasc Surg 2000; 119:297-304)
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A dvances in techniques to introduce exogenousgenetic material into mammalian somatic cells have
laid the foundation to treat inherited and acquired dis-
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in the United States), in comparison with 1062 in
December 1995. This increase of more than 1000
patients in a year reflects the worldwide enthusiasm for
using gene therapy to treat various human diseases.1,2
Gene transfer into the lung has the potential to be a
powerful treatment for pulmonary disease. In lung
transplantation, gene transfer into the donor lung graft
is feasible and may be useful in reducing ischemia-
reperfusion injury and rejection. Recently, our labora-
tory has demonstrated the beneficial effects of gene
transfer in ischemia-reperfusion injury and acute rejec-
tion in a rat lung graft model using adenovirus vectors,
cationic lipid vectors, or naked plasmid.3-5
The transplanted lung has been shown to express
transgene products when the vector was administered
either endobronchially or intravenously.3,5 With an ade-
noviral vector delivered intravenously in vivo, no evi-
dence of recombinant β-galactosidase reporter gene
expression was observed by either gross or microscop-
ic examination of the lungs.6 However, we3 recently
demonstrated that β-galactosidase reporter gene
expression was detectable, albeit in a small percentage
of cells, in the endothelium of pulmonary vessels after
intravenous adenovirus transfection.
Nitric oxide (NO), a potent vasodilator, is a free rad-
ical gas synthesized from L-arginine by NO synthases.
NO regulates vascular tone, inhibits smooth muscle cell
proliferation and migration, inhibits platelet aggrega-
tion, inhibits leukocyte adhesion, and scavenges super-
oxide anions.7 In experimental lung transplantation, we
have previously demonstrated that inhaled NO reduces
lung graft reperfusion injury when administered to the
donor before harvest8 or to the recipient after trans-
plant.9 We have also demonstrated the beneficial effect
of inhaled NO in human allograft reperfusion injury.10
Therefore overexpression of endothelial constitutive
NO synthase (ecNOS) in transplanted lung grafts might
reduce subsequent lung graft ischemia-reperfusion
injury. The aims of this study were to use an in vivo
adenoviral ecNOS gene transfection strategy to accom-
plish ecNOS overexpression in rat lung isografts and to
determine the effect of ecNOS on subsequent ischemia-
reperfusion injury in a rat lung isograft model.
Materials and methods
The first group of experiments (nontransplant setting,
groups E-I, E-II, and E-III) aimed to demonstrate in vivo
intravenous gene delivery and to confirm gene expression.
The second group of experiments (transplant setting, groups
I, II, and III) aimed to evaluate the effect of ecNOS gene
transfection in a rat lung isograft model after 18 hours of cold
preservation.
Animals. F344 rats (Harlan Sprague-Dawley Inc,
Indianapolis, Ind), weighing 250 to 270 g, were used in all
experiments. All animal procedures were approved by the
Animal Studies Committee at Washington University. Ani-
mals received humane care in compliance with the “Princi-
ples of Laboratory Animal Care” formulated by the National
Society for Medical Research and the “Guide for the Care
and Use of Laboratory Animals” prepared by the National
Academy of Sciences and published by the National
Institutes of Health (NIH publication 85-23, revised 1985).
Adenoviral vectors. AdCMVNOS is a replication-defi-
cient adenoviral vector encoding the ecNOS gene, driven by
the cytomegalovirus immediate early promoter, as described
in detail elsewhere.11 It was provided as a gift by Dr Timothy
O’Brien (Divisions of Endocrinology and Metabolism
Medicine, Mayo Clinic, Rochester, Minn).
First-generation replication-deficient adenovirus serotype
5 carrying the Escherichia coli LacZ gene encoding for β-
galactosidase and driven by the constitutive cytomegalovirus
promoter (AdCMVβ-gal) served as controls. It was provided
as a gift from the Gene Therapy Center at the University of
North Carolina Chapel Hill, North Carolina.
Adenoviral amplification was done by propagation in 293
cells to obtain high titer stocks, as determined by the plaque
assay (courtesy of Dr R. Jude Samulski and Dr Douglas
McCarty, Gene Therapy Center Vector Core Facility,
University of North Carolina, Chapel Hill, North Carolina).
Purified viral aliquots were stored at –80°C in 10% glycerol
buffered with 10 mmol/L Tris, 140 mmol/L NaCl, and 1
mmol/L MgCl2. Immediately before use, these stocks were
thawed and diluted in 1 mL of sterile normal saline solution.
Experimental groups
Experiment 1 (nontransplant setting)
EXPRESSION OF ECNOS GENE (GROUPS E-I, E-II, AND E-III).
These experiments were performed to demonstrate in vivo
gene delivery and to confirm gene expression. The rats were
divided into 3 groups (3 per group). In groups E-I and E-II,
animals received by jugular injection 5 × 109 plaque-forming
units (pfu) of adenovirus encoding ecNOS (group E-I) or β-
galactosidase (group E-II). In group E-III, rats were injected
with normal saline solution. Animals were killed 24 hours
after injection and lung grafts were harvested. The expression
of recombinant ecNOS gene was determined by immunohis-
tochemistry and Western blot analysis as described below.
Experiment 2 (transplant setting)
EFFECTS OF ECNOS GENE TRANSFECTION (GROUPS I, II, AND
III). Animals were randomly divided into 3 groups. Donor
animals received 5 × 109 pfu of adenovirus encoding ecNOS
(group I, n = 6), 5 × 109 pfu of adenovirus encoding β-galac-
tosidase as adenoviral controls (group II, n = 6), or normal
saline solution without adenovirus (group III, n = 6). Twenty-
four hours after injection, organs were harvested by means of
a standard technique described earlier3-5 and were preserved
for 18 hours at 4°C. Orthotopic left lung transplants were
then performed in isogeneic recipients. Recipients were
killed to assess the lung function 24 hours later.
Rat lung transplantation. Animals were anesthetized by
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a subcutaneous injection of ketamine chloride (25 mg/kg)
and atropine sulfate (0.25 mg/kg). After endotracheal intuba-
tion with a 14-gauge catheter, the animals’ lungs were
mechanically ventilated with a small-animal Harvard ventila-
tor (Harvard Apparatus Co, Inc, S Natick, Mass) (tidal vol-
ume: 2.5 mL; respiratory rate: 60 breaths/min) with 0.5%
halothane and 99.5% oxygen. A small incision was made in
the left lower part of the neck and the left external jugular
vein was mobilized. Normal saline solution (1 mL), either
alone (groups E-III, III) or containing 5 × 109 pfu of adeno-
virus encoding ecNOS (groups E-I, I) or β-galactosidase
(groups E-II, II), was injected intravenously over a period of
20 minutes. The incision was then closed and the animals
were allowed to recover from anesthesia.
Twenty-four hours after gene transfection, donor lungs
were harvested as described below. In brief, after general
anesthesia, mechanical ventilation, and systemic hepariniza-
tion, donor rat lungs were flushed through the main pul-
monary artery with 20 mL of cold (4°C) low-potassium dex-
tran–1% glucose solution at 20 cm H2O pressure. The
heart-lung block was then removed with the lungs inflated at
end-tidal volume. The left lung was stored for 18 hours at 4°C
in low-potassium dextran–1% glucose solution until implan-
tation. Recipient animals were anesthetized, intubated, and
subjected to a left thoracotomy. The pulmonary vessels and
bronchus were anastomosed by a modification of the previ-
ously described “cuff technique.”12 Ventilation and perfusion
were restored and a temporary chest tube was placed, which
was removed after recovery from anesthesia.
Immunohistochemistry. The labeled streptavidin biotin
technique was used. Lungs were perfused through the pul-
monary arterial trunk with 20 mL of normal saline solution
and 20 mL of HistoChoice solution (Amresco, Solon, Ohio).
The specimens were fixed in HistoChoice fixative for 24
hours at 4°C and embedded in paraffin wax. Tissue sections
7 µm thick were cut on a microtome and mounted on slides.
After deparaffinization, the sections were pretreated with
Dako Target Retrieval Solution (Dako, Carpenteria, Calif)
applied with steam at 95°C for 30 minutes and were preincu-
bated with SuperBlock Blocking Buffer in TBS (Pierce
Chemical Company, Rockford, Ill) for 30 minutes at room
temperature. The sections were incubated with a mouse anti-
ecNOS immunoglobulin G1 monoclonal antibody (Trans-
duction Laboratories, Lexington, Ky) at 1:50 dilution in
blocking solution (consisting of 10% SuperBlock, 10% nor-
mal goat serum in TBS/0.2% Triton X [Union Carbide,
Danbury, Conn]) or without primary antibody in blocking
solution at 4°C overnight. After unbound primary antibodies
were washed off with TBS/0.2% Triton X solution, the sec-
tions were incubated with biotinylated goat anti-mouse
immunoglobulin G antibody for 30 minutes, followed by
incubation with alkaline phosphatase–conjugated strepta-
vidin (Dako) for 30 minutes at room temperature. After wash-
ing with TBS and immerse detection buffer (consisting of
100 mmol/L Tris, 500 mmol/L NaCl, 50 mmol/L MgCl, pH
9.5), specific binding was detected by means of the
BCIP/NBT substrate working solution (Vector Laboratories,
Burlingame, Calif) containing 5 mmol/L levamisole (Vector
Laboratories) at room temperature for 10 minutes. The slides
were then counterstained with nuclear fast red dye, dehydrat-
ed with graded alcohol and xylene, mounted, and covered
with a coverslip.
Western blot analysis of ecNOS. The presence of ecNOS
was assessed by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS/PAGE) and Western immunoblotting as
previously described.3,13 In brief, frozen specimens were
homogenized in cold buffer A (consisting of 10 mmol/L
Tris/HCl, pH 7.5; 250 mmol/L sucrose; and 0.1 mmol/L
phenylmethylsulfonyl fluoride) using a ratio of 2 mL buffer
A per gram of tissue. The homogenate was centrifuged at
30,000g for 10 minutes at 4°C. The supernatant was removed,
rapidly frozen, and stored at –80°C until analysis. Protein
content of the supernatant was measured by ultraviolet spec-
trophotometry. Thereafter, 20 µg total protein was loaded in
each lane. Proteins were separated by SDS/PAGE on 0.75-
mm thick, 12.5% acrylamide gels. The proteins on the gel
were immediately transferred to nitrocellulose membranes
(Hybond C, Amersham, Bucks, United Kingdom) for
Western blotting. The membrane was then incubated at room
temperature for 1 hour with a mouse anti-ecNOS immuno-
globulin G1 monoclonal antibody at 1:1500 dilution. After
repeated washings, the membrane was incubated with perox-
idase-labeled anti-mouse second antibody (at 1:1000 dilution
at room temperature for 1 hour) and then with enhanced
chemiluminescence detection reagent (Amersham Inter-
national Ltd, Little Chalfont, Bucks, United Kingdom). The
nitrocellulose paper was then exposed to Fujifilm Medical X-
Ray film (Fuji Photo Film Co, Tokyo, Japan). Human
endothelial lysate served as a positive control (Transduction
Laboratories). The degree of ecNOS expression was semi-
quantitatively evaluated with computed densitometry with
the use of NIH image software (National Institutes of Health,
Bethesda, Md).
Effects of ecNOS gene transfection. After 24 hours of
reperfusion, recipient animals were reanesthetized by means
of the donor technique described above, and their lungs then
were mechanically ventilated with 100% oxygen. Median
laparotomy-sternotomy was performed and the contralateral
right hilum was clamped. The animals’ lungs were then ven-
tilated for 5 minutes with a tidal volume of 1.5 mL, respira-
tory rate of 100 breaths/min, and positive end-expiratory
pressure of 1.0 H2O to assess the function of the lung isograft
by arterial blood gas analysis using blood samples obtained
from the ascending aorta. After the animal was put to death,
each left lung graft was divided into two specimens: the lower
half was snap-frozen in liquid nitrogen for myeloperoxidase
activity measurements, and the remaining upper half was
weighed, dried at 80°C for 48 hours, then weighed again for
calculation of the wet/dry weight ratio.
Myeloperoxidase activity. Quantitative myeloperoxidase
activity was determined as previously described.3,14 Optical
density (OD) was measured at 460 nm with a spectropho-
tometer (model PMQ II, Carl Zeiss, Oberkochen/Wuett,
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Germany). Color development was linear from 5 to 20 min-
utes. One unit of enzyme activity was defined as the amount
of 1.0 OD units per minute per milligram of tissue protein at
room temperature.
Statistical analysis. Values are reported as mean ± stan-
dard error of the mean. Data were analyzed after logarithmic
correction. One-way analysis of variance with pairwise com-
parison by the Fisher protected least significant difference
method was used to compare overall differences among
groups.
Results
Experiment 1 (nontransplant setting)
Immunohistochemistry of ecNOS. Positive immuno-
histochemical staining for ecNOS was observed in the
endothelium of vessels in ecNOS transfected lungs (Fig
1, A and B). This was not seen in lungs transfected with
either β-galactosidase (Fig 1, C) or flushed with saline
solution alone (Fig 1, D). Weak and patchy staining in
airway epithelial cells was present in all 3 groups. No
staining of smooth muscle, macrophages, or alveolar
parenchyma was observed in any of the groups.
Western blot analysis of ecNOS. Western blotting
identified a single band of protein from the detergent-
extracted homogenate with an estimated molecular
mass of 140 kDa for ecNOS in all groups, correspond-
ing to the endogenous ecNOS present in rat lungs (Fig
2, top). At least 2-fold higher expression of ecNOS pro-
tein was present in animals that had been transfected
with ecNOS (group E-I) than in the other 2 groups (Fig
2, bottom).
Experiment 2 (transplant setting) 
Arterial blood gas analysis. Left lungs from group I,
which had been transfected with ecNOS, had better
arterial oxygen (PaO2) levels than groups II or III. A
mean PaO2 of 166.48 ± 38.3 mm Hg was obtained from
group I animals compared with 71.7 ± 8.9 mm Hg for
group II and 67.8 ± 12.2 mm Hg for group III. This dif-
ference between group I versus groups II or III was sta-
tistically significant with P = .01 for group I versus II
and P = .03 for group I versus III.
Mean arterial carbon dioxide tensions were not sig-
nificantly different in any of the groups (23.4 ± 5.3,
29.8 ± 3.4, and 23.3 ± 3.9 mm Hg for groups I, II, and
III, respectively, P > .5).
Myeloperoxidase activity. Myeloperoxidase activity,
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Fig 1. Immunohistochemistry for ecNOS gene expression in rat lungs. Strongly positive ecNOS staining was
observed in the vascular endothelium of ecNOS-transfected lungs (A, 100× magnification; B, 400×), but not in
β-galactosidase–transfected lungs (C, 100×) or normal lungs (D, 100×).
a reflection of tissue neutrophil sequestration, in lung
homogenates was significantly reduced in group I com-
pared with groups II and III. Myeloperoxidase activity
in group I was 0.136 ± 0.038 ∆OD/mg/min versus
0.587 ± 0.077 ∆OD/mg/min for group II and 0.489 ±
0.126 ∆OD/mg/min for group III. This corresponded to
P = .001 for group I versus II and P = .01 for group I
versus III.
Wet/dry weight ratio. Mean wet/dry weight ratios in
all groups were not significantly different. For group I,
an average wet/dry weight ratio of 6.0 ± 0.6 was
obtained, versus 6.1 ± 0.4 for group II and 6.2 ± 0.3 for
group III (P > .9 for group I vs II and group I vs III).
Discussion
In clinical lung transplantation, significant graft dys-
function has been reported in 15% to 20% of cases.15,16
Early graft dysfunction is an acute lung injury accom-
panied by vascular permeability that is presumably
related to ischemia-reperfusion injury. The exact patho-
physiologic mechanisms of ischemia-reperfusion
injury remain unclear. A variety of factors have been
implicated in its pathogenesis, including activation of
increased production of neutrophils and platelets,
cytokines, and oxygen-derived free radicals.17-19
In normal situations, NO synthesized by constitutive
NOS in endothelial cells inhibits leukocyte adhesion
and platelet aggregation. However, after ischemia-
reperfusion, ecNOS and NO production levels decrease,
leading to increased leukocyte adherence to the
endothelium. Various cytokines produced by these
inflammatory cells induce inducible NOS in endothelial
cells, smooth muscle cells, leukocytes, and macro-
phages, resulting in large quantities of NO.20 This is
known to react with superoxides produced after
ischemia-reperfusion by endothelial cells, leukocytes,
and macrophages and to react rapidly to form the stable
peroxynitrate anion (ONOO–). The cytotoxicity caused
by ONOO– is known to be one of the most important
factors modulating ischemia-reperfusion injury.21
Several strategies have been shown to reduce
ischemia-reperfusion injury of organs, such as the use
of prostaglandins, nicorandil, and free radical scav-
engers.22-24 Recently, the use of inhaled NO has been
reported to significantly reduce lung allograft
ischemia-reperfusion injury presumably by altering
vascular tone, inhibiting platelet aggregation, inhibit-
ing leukocyte adhesion, and scavenging superoxide
anions.8-10,25 In the present study, myeloperoxidase lev-
els were significantly reduced in ecNOS-transfected
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Fig 2. Western blot analysis of ecNOS in lung tissue. Lane 1 represents a positive control, lanes 2 to 4 represent
group I (ecNOS-transfected lungs), lanes 5 to 7 represent group II (β-galactosidase–transfected lungs), and lanes
8 to 10 represent group III (saline controls). The histogram shows semiquantitative comparisons between these
groups after measurement of relative densitometry. Each bar represents mean ± standard error of spectrophoto-
metric analysis of blots with 3 samples within each group.
lungs. As myeloperoxidase activity reflects tissue neu-
trophil sequestration, ecNOS gene transfection may
have supplemented the reduced NO production seen
after ischemia-reperfusion, inhibited neutrophil adhe-
sion, and thereby decreased ischemia-reperfusion
injury. However, the improvement seen in lung oxy-
genation varied widely. In addition, there were no sig-
nificant differences between groups in wet/dry lung
ratio. This observation is perplexing and may be due to
less than optimal gene transfection efficiency accom-
plished by this in vivo intravenous application. If the
optimal degree of gene expression can be identified and
accomplished by this in vivo approach, more efficient
ecNOS gene transfection may produce more uniform
reduction in reperfusion injury. The ischemia-reperfu-
sion model we used in this experiment has been used by
our group to investigate a variety of therapeutic strate-
gies.3,4 It produces a uniformly severe injury in control
animals. Perhaps a lesser degree of ischemia-reperfu-
sion injury might have had a more consistent response
to this transfection strategy.
We have previously reported that the ex vivo route
(administered to the graft after harvest) is a more effi-
cient means of lung graft transfection.26 However,
when this strategy is used, transgene expression is not
observed for 1 to 2 hours after reperfusion. To have an
impact on the events of reperfusion, we thought that the
transgene must be present at the time of reperfusion.
With presently available technology, that requirement
mandates an in vivo approach. Western blot analysis
confirmed the overexpression of ecNOS in ecNOS-
transfected lungs. These results point to the feasibility
of a donor-directed intravenous approach of gene trans-
fection into pulmonary vascular cells. We have not
studied the long-term effects of adenovirus encoding
ecNOS or how long these effects will be present,
because the transgene expression does not need to last
a long period to prevent reperfusion injury. However,
Champion and associates27 used an in vivo study of the
long-term effects and expression of AdCMVecNOS
delivered in lungs.27 In mice treated with
AdCMVecNOS, the maximum augmentation of pul-
monary vasodepressor response to bradykinin was
observed 1 day after transfection, and the responses to
bradykinin were significantly different from control
responses 7 days after transfection. The augmented
decrease in pulmonary arterial pressure in response to
bradykinin returned to the baseline response level 7 to
14 days after transfection with AdCMVecNOS.
Adenovirus-mediated cytotoxicity or inflammation has
been discussed as a potential problem by other investi-
gators.28,29 In our study, no inflammatory response was
seen in histologic sections stained with hematoxylin
and eosin. However, we did not specifically investigate
host cytotoxicity or immune responses to adenoviral
administration.
In conclusion, systemic administration of a recombi-
nant adenoviral vector encoding ecNOS gene resulted
in increased ecNOS protein in lung grafts, which
reduced lung isograft ischemia-reperfusion injury, as
manifested by significantly improved oxygenation and
decreased neutrophil sequestration. We believe that
ecNOS gene transfer may reduce acute lung dysfunc-
tion after lung transplantation.
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Discussion
Dr Vaughn Starnes (Los Angeles, Calif). Dr Suda and
associates are to be congratulated on a very fine experimen-
tal model. I would like to summarize it a bit for the associa-
tion. Basically, he had 3 experimental groups. One received
the ecNOS adenovirus vector to produce endogenous NO to
ameliorate the effects of ischemic reperfusion. The second
group was designed to look at the reporter gene to assess the
transfection efficiency. A third group was basically saline
control. The hypothesis was that administration of the ecNOS
gene could increase endogenous synthesis of NO, therefore
limiting the injury that can occur after reperfusion ischemic
injury. Dr Suda, if that is the hypothesis, did you actually
measure endogenous ecNOS before ischemia such that you
have a baseline?
Dr Suda. The Western blot and immunohistochemistry
studies were performed before reperfusion. Therefore the
results in the control groups show endogenous ecNOS.
Dr Bryan F. Meyers (St Louis, Mo). I am one of Alec
Patterson’s colleagues and am backing up Dr Suda in Dr
Patterson’s absence. The Western blot and the immunohisto-
chemical results that were shown were obtained 24 hours
after transfection but before cold storage and reimplantation.
I think the missing information you are looking for is actual-
ly the immunohistochemical and the Western blotting results
after the cold storage and insertion to show that there is a
diminished ecNOS in the nontreated animals. The Western
blot and immunohistochemistry that he showed were in the
nonischemic animals. The studies were done 24 hours after
transfection, just before those lungs became graft lungs.
Dr Starnes. As you mentioned, the oxygenation and
myeloperoxidase data that would suggest decreased leuko-
cyte sequestration in the lung were quite variable. They seem
to suggest benefit from the adenoviral transfection of ecNOS
into the graft. Was this variability due to a transfection effi-
ciency, or was it due to effects of cold storage on the vector
itself? In other words, did you think the number of endothe-
lial cells were 30% transfected, 20% reliably, 100%, or could
it have been that they were variably transfected?
Dr Suda. The variability of results may be due to less than
optimal gene transfection efficiency accomplished by this in
vivo intravenous application. I do not know the number of
endothelial cells that were transfected.
Dr Starnes. If you had a group that had the reporter gene
in it, β-galactosidase marker, why did you not give us that
information as staining data to provide some idea of the trans-
fection efficiency after cold storage?
Dr Suda. Our previous study, reported by Dr Hiratsuka,
demonstrated that β-galactosidase reporter gene expression
was detectable in the endothelium in pulmonary vessels, so
we did not perform that in this study. 
Dr Meyers. Just to amplify, one of Dr Suda’s coauthors on
this paper, Dr Hiratsuka, is publishing an article in The
The Journal of Thoracic and
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Annals of Thoracic Surgery, which evaluates a very similar
laboratory model looking at heat shock protein. He also used
β-galactosidase as a control and used the bluo-gal assay after
ischemia and reperfusion to show the transfection of the pul-
monary endothelial cells with β-galactosidase. There was dif-
fuse staining throughout the pulmonary vasculature, although
it is fairly spotty, and I cannot recall the actual percent of cells
that had the bluo-gal assay.
Dr Starnes. Given the concern about systemic effects of
intravenously administered adenoviral vectors, did you con-
sider administering this by the endobronchial route, that is, by
aerosolizing vector into the lung grafted cell?
Dr Suda. Because it is difficult to transfect the pulmonary
endothelium through airway administration, I think that is not
a suitable method for ischemia-reperfusion injury. I have
never heard of a successful functional study in lung trans-
plantation for ischemia-reperfusion injury in which the air-
way was used, so we chose intravenous administration to
transfect the endothelium of the pulmonary vessels. 
Dr Starnes. These adenoviral vectors are not like antibi-
otics. They can transfect and they can infect all sorts of
organs as they are administered, so the fact that you were
able to record it and transfect the lung tissue also means you
probably were able to transfect the kidney and the heart and
anywhere else you had endothelium. As we use these vec-
tors, they are going to have to be targeted in some way to
the specific organ of interest. That is the reason I ask the
question.
Dr Meyers. Dr Hiratsuka’s article also showed that in the
animals that were pretreated 24 hours in advance of lung
donation, there was staining in the kidneys and in the liver.
This sort of treatment would be unacceptable for multiorgan
donors in a human situation. One of the limitations of gene
therapy in organs that are about to be put in cold storage is
that you need to have them being expressed at the time of cold
storage for there to be an effect immediately on reperfusion.
Given the constraints that Dr Suda and his group had regard-
ing the available vectors and genes to transfect, this was their
best compromise.
Dr Michael Grosso (Browns Mills, NJ). I want to congrat-
ulate you but also the Association for continuing to support
basic science in this age of managed care. Given Dr Starnes’
comments, since it does require 24 hours before harvest to
transfect these, where do you see us heading in terms of being
able to overcome these obstacles in the clinical setting?
Dr Suda. In previous studies, gene expression was present
as early as 6 hours after intravenous injection, and it signifi-
cantly increased after 24 hours; however, clinical extended
exposure time may not be suitable in the setting of organ
transplantation. Therefore we chose this time frame to
demonstrate the effectiveness of gene transfection for ecNOS
within the setting of ischemia-reperfusion injury. We did not
test shorter time frames. More efficient vectors and systems
for gene therapy will possibly permit shorter time frames to
accomplish significant levels of transgene protein expression.
Dr Grosso. The literature is beginning to suggest, at least
at the laboratory level, that lung ischemia reperfusion may be
more responsible for bronchiolitis obliterans and graft failure
over the long term in these transplants than actual chronic
rejection. How do you feel about that? 
Dr Meyers. I do not think he can answer that question
based on the work he has done for this paper. 
Dr Michael Jaklitsch (Boston, Mass). β-Galactosidase,
although very useful in in vitro models, has numerous pitfalls
in vivo. In particular, mast cells will artificially express the
gene product for β-galactosidase. Many laboratories that are
working in this field have turned to the luciferase gene to try
to avoid these problems in the in vivo model. I would refer
you to an article in Circulation in 1993, which shows the
problem of β-galactosidase in an in vivo rabbit model.
Dr Meyers. Dr Suda was somewhat handcuffed by what
was available in the laboratory at the time. I think that on the
basis of today’s experience he has the next few months of
experiments lined up.
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